(Q41435904)

English

Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial

scientific article published on 15 February 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

0 references

1 reference

based on heuristic

inferred from title

Philip J. Coates

2

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

object named as

Vuk Stambolic

9

0 references

object named as

Colin A Purdie

7

0 references

Pamela J Goodwin

object named as

Pamela J Goodwin

8

0 references

author name string

Sirwan M Hadad

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Lee B Jordan

3

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Ryan J O Dowling

4

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Martin C Chang

5

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Stacy Moulder-Thompson

10

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Alastair M Thompson

11

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

language of work or name

0 references

publication date

15 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

150

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

149-155

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Metformin and reduced risk of cancer in diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Sulphonylureas and cancer: a case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Molecular pathways: preclinical models and clinical trials with metformin in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Metformin and other biguanides in oncology: advancing the research agenda

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

AMPK: a nutrient and energy sensor that maintains energy homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Histological evaluation of AMPK signalling in primary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

AMP-activated protein kinase induces a p53-dependent metabolic checkpoint

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Targeting AMPK: a new therapeutic opportunity in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Clinical pharmacokinetics of metformin

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

The effect of metformin on apoptosis in a breast cancer presurgical trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3307-5

21 January 2018

Identifiers

10.1007/S10549-015-3307-5

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41435904&oldid=2204533548"